Pluristem’s Proprietary PLX Cells Demonstrate Promising Potential in Treating Autoimmune Disorders
News Nov 29, 2007
Pluristem Therapeutics, Inc. has announced that in vitro testing of its PLacenta eXpanded (PLX) cells demonstrated the potential to treat autoimmune disorders. This testing showed a significant reduction of TNF-a and interferon-? inflammatory cytokines that are known to be involved in the pathogenesis of autoimmune disorders.
Reducing TNF-a and interferon-? is considered a key factor in mitigating the symptoms of autoimmune disorders, such as Multiple Sclerosis (MS), Rheumatoid Arthritis (RA), Crohn’s Disease and Juvenile (Type 1) Diabetes.
“We are excited that our PLX cells demonstrate the potential to treat autoimmune disorders,” said Zami Aberman, Pluristem’s President and CEO.
“The strong anti-inflammatory results show that our PLX cells may have the capability to help millions of patients and represent an additional potential multi-billion dollar market for our PLX cells. These impressive results suggest that our 3D-expanded placental cells could become an allogeneic, non-controversial source for stem cell therapeutics in the future,” continued Aberman.
The spatial and temporal dynamics of proteins or organelles plays a crucial role in controlling various cellular processes and in development of diseases. However, acute control of activity at distinct locations within a cell cannot be achieved. A new chemo-optogenetic method enables tunable, reversible, and rapid control of activity at multiple subcellular compartments within a living cell.